Targeted HBB Locus Integration in Hematopoietic Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for α-thalassemia, such as frequent blood transfusions and allogeneic hematopoietic stem cell transplantation, are associated with significant safety and efficacy issues, including immune rejection and graft-versus-host disease, and do not adequately address the genetic cause of the disease.
Innovation Solution
The method involves genetically modifying hematopoietic stem and progenitor cells (HSPCs) by introducing a guide RNA that targets an intron of the HBB gene, an RNA-guided nuclease, and a donor template containing a transgene encoding an α-globin protein. This integration results in the expression of α-globin protein in the genetically modified HSPCs, aiming to restore the balance between alpha and beta globin chains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic hematopoietic stem cell transplantation is performed, then curative effect is improved, but risk of immune rejection and graft-versus-host disease increases
Solution Approach 1:
The invention separates the curative function (alpha-globin production) from the immune compatibility issue by using autologous cells. The HSPCs are isolated from the patient's own bone marrow, avoiding alloimmune reactions while maintaining the ability to produce functional hemoglobin.
Solution Approach 2:
The invention introduces an intermediary mechanism (CRISPR-Cas9 genome editing system) to correct the genetic defect in autologous HSPCs. This intermediary technology enables the patient's own cells to produce functional alpha-globin without requiring donor cells, thus avoiding immune rejection while achieving curative effect.
2Quantity of substance
If frequent blood transfusions are administered, then alpha-globin deficiency is compensated, but iron overload and treatment burden increase
Solution Approach 1:
The invention performs preliminary genetic correction of HSPCs before they differentiate into red blood cells. By correcting the alpha-globin gene defect at the stem cell level, the system establishes a long-term endogenous source of functional alpha-globin, eliminating the need for repeated transfusions and avoiding iron overload.
Solution Approach 2:
The genetically corrected autologous HSPCs serve as a self-sustaining system that continuously produces functional alpha-globin chains. The patient's own modified HSPCs engraft and differentiate to produce hemoglobin with balanced alpha and beta chains, creating a self-service solution that eliminates dependency on external transfusions.
3Quantity of substance
If existing gene therapy approaches are used, then alpha-globin expression is increased, but integration safety and genomic stability are compromised
Solution Approach 1:
The invention replaces traditional mechanical/viral integration methods with a precision molecular system (CRISPR-Cas9). Instead of relying on viral vectors that randomly integrate and carry safety risks, the CRISPR system uses guide RNA to direct Cas9 nuclease to a specific genomic location (HBB intron 2), enabling precise, controlled integration of the alpha-globin transgene without random insertion mutagenesis.
Solution Approach 2:
The invention changes the integration parameter from random to targeted by using the HBB intron 2 locus as a specific integration site. This targeted approach at a well-characterized genomic location with active transcription ensures safe integration away from critical genes while maintaining high alpha-globin expression through the endogenous HBB promoter and enhancer elements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially provides a safe and effective means to increase alpha globin levels in red blood cells, thereby ameliorating symptoms of α-thalassemia and reducing the need for frequent blood transfusions and other treatments.
Implementation Method 1
the RNA-guided nuclease cleaves the intron of the HBB gene sequence in the cell
Implementation Method 2
introducing into the HSPC a guide RNA comprising a sequence that hybridizes to an intron of an HBB gene sequence
Implementation Method 3
the transgene is integrated into the cleaved HBB gene sequence; the donor template comprises a first homology arm located 5′ of the transgene, the first homology arm corresponding to at least 200 nucleotides of the HBB gene sequence
Data Source
AI summary
The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBB locus in the HSPCs with a transgene encoding alpha globin.